EGFR and non-small cell lung carcinoma: Initial clinical trials of oral EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, demonstrated moderate efficacy in unselected NSCLC patients’ post-chemotherapy, with response rates around 10% and a median survival extension of 2 months compared to placebo (Kim et al., 2008; Shepherd et al., 2005).